8-KFiled Aug 12, 8:00 PM ET

Eton Pharmaceuticals Reports Q2 2026 Financial Results

$ETON · Eton Pharmaceuticals, Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

Eton Pharmaceuticals Reports Q2 2026 Financial Results

What Happened
Eton Pharmaceuticals, Inc. (ETON) filed a Form 8-K on August 13, 2026 under Item 2.02 to announce its results of operations and financial condition for the quarter ended June 30, 2026. The company issued a press release reporting its Q2 2026 financial results, which is attached to the filing as Exhibit 99.1.

Key Details

  • Filing date: August 13, 2026 (Form 8-K, Item 2.02).
  • Reporting period: Quarter ended June 30, 2026 (Q2 2026).
  • The press release with the specific financial figures and commentary is attached as Exhibit 99.1 to the 8-K.
  • The 8-K also includes the Inline XBRL cover page (technical filing component).

Why It Matters
This 8-K is Eton’s formal disclosure that it has released its Q2 2026 earnings and related financial information. Investors should review the attached press release (Exhibit 99.1) for the company’s reported revenue, net income/loss, cash position, and management commentary, since those figures will inform near-term valuation, guidance expectations, and trading reactions.